SCRI Oncology Partners /ID# 275686

Nashville, Tennessee 37203

1 studies enrolling now · 1 studies all time

What they study most

Solid Tumors Harboring MET Amplification

Studies at this site

• A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan — Recruiting now